The World Health Organization (WHO) announced Covid-19 disease as a pandemic caused by SARS-CoV-2 which has reached 204 countries and territories. Around 15 lakh people are infected and about 1 lakh have died till April 8, 2020. A global social and economic stress have been observed. SARS-CoV-2 is a rapidly evolved zoonotic single strand, positive sense RNA virus belonging to the genus betacoronavirus which contains structural and nonstructural proteins. It transmits through airborne droplets and rapidly spreads through person-to-person contacts in the human population. It causes both upper and lower respiratory tract disease to be associated with more severe illnesses, such as bronchitis, bronchiolitis, pneumonia, organ failure and respiratory distress syndrome. The symptoms of Covid-19 are fever, tiredness, dry cough, sore throat and difficulty in breathing. 5-10% people require critical care subjected to ventilation. Medicines are being used in combinations worldwide to overcome the disease. On the basis of research findings, we hypothesize that antimalarial drugs, regular BCG vaccination and higher temperature may reduce the infectivity of Covid-19. Physical distancing is a potential way to control community transmission of the pandemic. Vaccination is required to mitigate Covid-19 virus, while vaccine development is subject to further research.

Keywords: COVID-19, physical distancing, transmission
get more infected as compared to younger one. The basic reproductive number (Ro) is estimated to be 2.0 (95% CI, 1.4 to 3.9) and Covid-19 doubles in size approximately every 7.4 days. (2020_10). The WHO has estimated mortality rate to be ~3.48 for Covid-19. Evidences showed that SARS-CoV-2 can survive from 3 hours in aerosol up to 72 hours on plastic, stainless steel, copper and cardboard surfaces.[6]

In March, 2003 an outbreak was observed in Hong Kong, causing a large amount of death due to respiratory disease which was named as SARS by the World Health Organization (WHO). In SARS, the neutrophil count and lactate dehydrogenase enzyme level were used as disease identification markers.[7] A similar outbreak was caused by Middle East respiratory syndrome coronavirus (MERS-CoV) in September 2012[8] which was not transmissible among humans like the SARS-CoV epidemic in 2003.[9] Serologic and genomic data confirmed that camels and bats act as intermediate hosts for human MERS-CoV and SARS-CoV, respectively.[10, 11] Recently, various kinds of studies were conducted worldwide which indicate that Malayan pangolin is the closest intermediate host (Fig. 3) for SARS-CoV-2 after Bat.[12]

The most common symptoms of COVID-19 are fever, tiredness, and dry cough. Body temperature more than 38 degrees Celsius (high fever) has been observed in covid-19 infected patients. Different case studies have shown that 20-25% people don’t develop any symptoms and don’t show any symptoms while they are infected, consequently they promote community transmission. Clinical investiga-
tions have revealed that most of the people recover from the disease.[13] Researchers showed interest in the presence of virus in feces but no evidence has been found yet.[14] Nasal, throat swab and sputum samples are being used for diagnostic purposes by health specialists. The data so far suggest that the virus has a case fatality risk around 1%; this rate would make it many times more severe than typical seasonal influenza, putting it somewhere between the 1957 influenza pandemic (0.6%) and the 1918 influenza pandemic (2%).[15] The Covid-19 pandemic caused worldwide shortage of hospital beds, ICU beds, and ventilators. The SARS-CoV-2 has a large economic and social impact on the human population. As still no potential therapy has been developed so lockdown has been implemented by different countries to weaken the viral spread.[16]

Classification

2019-nCoV named as SARS-CoV-2 by considering its taxonomic and genomic relationships with the species of severe acute respiratory syndrome-related coronaviruses.[17] Phylogenetic studies have established that SARS-CoV-2 was distinct from SARS-CoV in a phylogeny of the complete RNA-dependent RNA polymerase (RdRp) gene and virus belongs to the subgenus Sarbecovirus (Fig. 4).[18] The genome of the SARS-CoV-2 showed similarity with bat-derived coronavirus strains, bat-SL-CoVZC45 and bat-SL-CoVZXC21, including the virus that caused the SARS outbreak of 2003.[19]

Structure and Genome Organization

In the past two decades, covid-19 is the third rapidly evolved zoonotic RNA coronavirus, emerged in the human population.[5, 20, 21] Zhang, Wu et al. conducted metagenomic study and established that Malayan Pangolin coronavirus (SARS-CoV2-like) show 91.02% and 90.55% similarity at genomic level to SARS-CoV-2 and BatCoV, respectively. This study has revealed the Pangolin-CoV as the most closely related CoV to SARS-CoV-2 after BatCoV. In Pangolin-CoV and SARS-CoV-2 five conserved amino acid residues interact with human ACE2, but in Bat-CoV mutations are present in four amino acid. A putative furin recognition sequence motif at the S1/S2 cleavage site was observed in the Covid-19, which was absent in both Pangolin-CoV and BatCoV.[12] The genome of Covid-19 has been sequenced and deposited to NCBI reported from different laboratories across the world. Updated sequence information has been provided in the Table 2. It has been found that covid-19 has a single, positive, sense stranded RNA. It contains 29,811 bp longs nucleotides (cDNA) broken down as follows: 8,903 (29.86%) adenosines, 5,482 (18.39%) cytosines, 5,852 (19.63%) guanines, and 9,574 (32.12%) thymines. Five mutations have been identified including T8782C (in ORF1a, codons AGT to AGC, silent mutation), T9561C (in ORF1a, codons TTA to

Table 2. List of genomes sequenced by different countries

| Accession Number | Strain/Origin               |
|------------------|-----------------------------|
| MN988668         | 2019-nCoV WHU01             |
| NC_045512        | Wuhan-Hu-1                  |
| MN938384.1       | 2019-nCoV_HKU-SZ-002a_2020 |
| MN975262.1       | 2019-nCoV_HKU-SZ-005b_2020 |
| MN988713.1       | 2019-nCoV/USA-IL1/2020     |
| MN994467.1       | 2019-nCoV/USA-CA1/2020     |
| MN994468.1       | 2019-nCoV/USA-CA2/2020     |
| MN997409.1       | 2019-nCoV/USA-AZ1/2020     |
| MN985325.1       | 2019-nCoV/USA-WA1/2020     |
| MT072688         | SARS-CoV-2/61-TW/human/2020/NPL |
| MT106054         | 2019-nCoV/USA-TX1/2020     |
| MT012098.1       | SARS-CoV-2/human/IND/29/2020 |
| MT050493.1       | SARS-CoV-2/human/IND/166/2020 |
TCA, non-silent mutation), C15607T (in ORF1b, codons CTA to TTA, silent mutation), C28144T (in ORF8b, codons TCA to TTA, non-silent mutation), and T29095C (in Nucleocapsid, codons TTT to TTC, silent mutation). Different types of protein sequences have been identified in the viral genome which code for various structural and nonstructural proteins. Structural proteins include RNA dependent RNA polymerase (RdRp), Spike protein (S), Envelope protein (E), Membrane protein (M), Nucleocapsid protein, 5' UTR and 3' UTR. Nonstructural proteins such as ORF3a, ORF7a, and ORF8 function as accessory proteins playing a role in viral pathogenesis. In a few studies, it was shown that mutation in SARS CoV-2 was present at nucleotide level in gene S, nsp1, nsp3 and nsp15 but not at amino acid level. In addition, the SARS-CoV-2 strain found in the US, the Nucleocapsid (N) protein gene has three mutations (28881G>A, 28882G>A, and 28883G>C). Studies have revealed that the N protein of SARS-CoV is responsible for the formation of the helical structure during virion assembly. The N protein has potential value in vaccine development because it may cause immune response. Also, mutations associated with spike glycoprotein have been found. The significant SNP mutation (23403A>G) occurred in the gene encoding spike glycoprotein (S protein: D614G). The mutation D614G is located in the putative S1–S2 junction region near the furin recognition site (R667) for the cleavage of S protein when the virus enters or exits cells. Spike glycoprotein structure was predicted in SARS-CoV-2 (Fig. 5) and two conformations, closed and open deduced via cryo-electron microscopy deposited to the protein data bank with pdb id 6VXX and 6VYB, respectively. It has been suggested that SARS-CoV polyclonal antibodies may inhibit SARS-CoV-2 spike mediated entry into cells. It has been found that the S1 domain of spike protein mediates an initial high-affinity association with their ACE2 receptor. Walls et al and Zhou et al have demonstrated experimentally that SARS-CoV-2 uses ACE2 (human angiotensin-converting enzyme 2) to enter inside the target cell and shows a similar affinity towards ACE2 as SARS-CoV. Consequently, the spike protein has been considered a viral target. The Mechanisms of viral entry may include membrane fusion upon receptor binding and induced conformational changes in spike protein followed by cathepsin L (CTSL) proteolysis which leads to activation of membrane fusion within endosomes. Yadav et al. demonstrates that the SARS-CoV-2 shares approximate 96% whole genome identity with a BatCoV (RaTG13), from Rhinolophus affinis from Yunnan Province.

Transmission

The epidemic of 2019 novel coronavirus (now called SARS-CoV-2, causing the disease Covid-19) has expanded from Wuhan throughout China and is being exported to a growing number of countries (Fig. 6), some of which have seen onward transmission. It has been seen in the transmission of sars-cov-2 in Thailand, where taxi driver get infected from close contact of Chinese tourists who wore masks, which indicates asymptomatic transmission. Local transmission has been identified as a case of locally transmitted infection in Taiwan from a wife (who returned from Wuhan, China) to her husband. Research findings have been shown that the potential cause for spreading of covid-19 infection is human to human transmission by close contact via airborne droplets generated by coughing and sneezing (Fig. 7). Tedros Ghebreyesus, director-general of the WHO, said that 41% of the Covid-19 cases in Wuhan resulted from hospital-related transmission. Also, it has been observed that during this pandemic, the important thing is to separate clinicians providing care from those making triage decisions. Subclinical symptomatic or asymptomatic persons are being considered potential sources of Covid-19 infection may warrant a reassessment of transmission dynamics of the current outbreak. Study conducted in various countries demonstrates that Covid-19 shows sustained transmission and supports the implementation of physical distancing measures to rapidly control the outbreak. Worldwide data of infected persons established that older people (mean age 45 year) get more infected as compared to younger one (Table 3). Also, case studies have been confirmed that Covid-19 occurred in children, causing moderate-to-severe respiratory illness, in the early phase of the SARS-CoV-2. It has been found that transmission of SARS-CoV-2 is affected by high tem-
Diagnosis

Covid-19 is pandemic in the human population and causes both upper and lower respiratory tract disease to be associated with more severe illnesses, such as bronchitis, bronchiolitis, pneumonia, exacerbations of asthma, organ fail
ure and respiratory distress syndrome. The virus could also invade CNS primarily through the olfactory route which is yet to be subject for further clinical investigation. Molecular and physiological studies have revealed that SARS-CoV-2 grows better in primary human airway epithelial cells. Increased level of C-reactive protein (13.9 mg per liter) was observed in covid-19 examination in patients reported from China. Research findings have shown that lymphocytopenia was present in 83.2% of the patients infected with coronavirus.

The 14 days period is the incubation time (Table 4) of SARS-CoV-2. The incubation time was defined by WHO as the interval between the potential earliest date of contact of the transmission source (wildlife or person with suspected or confirmed case) and the potential earliest date of symptom onset (i.e., cough, fever, fatigue, or myalgia). Based on worldwide clinical data it has been established that only 5-15% of infected people face severely ill conditions and develop difficulty breathing. Research findings have shown that older age people with high blood pressure, heart problems or diabetes etc are more likely to develop serious illness and seek medical attention. Scientific strategies for diagnosis of viruses are in the public domain such as RT-PCR based methods, paper-strip tests associated with CRISPR, viral RNA genome sensing based techniques. Researchers have revealed that the antibody based algorithms should have been implemented for SARS-CoV-2 in samples collected from throat swabs and serum. World-wide clinical studies have suggested the use of oseltamivir and oxygen therapy, mechanical ventilation, systemic glucocorticoids to severe patients.

### Treatment and Prevention

Physical distancing is an alternative way to restrict the viral spread, applied by various countries. It includes isolating ill persons (including voluntary isolation at home), quarantine suspected people, school closures, and telecommuting where possible. In public health practice, “quarantine” refers to the separation of persons (or communities) who have been exposed to an infectious disease and “Isolation,” in contrast, applies to the separation of persons who are known to be infected. Researchers have suggested potential drug therapies including antiviral medication of interferon-1β, the RNA polymerase inhibitor remdesivir, chloroquine, and a variety of traditional medicine. Doctors have treated covid-19 patients with combination of drugs being used in HIV, Swine flu and malaria; lopinavir–ritonavir (200 mg and 50 mg, respectively) twice a day for 14 days, Oseltamivir, Chloroquine are used in swine flu and malaria treatment, respectively. In-silico methods should be employed for the development of vaccines and potential targets are subjected to find out. Day by day case dynamics has revealed that the most problematic situation will be the urgent requirement of mechanical ventilation. So far, data on case fatalities have shown that 5%-6% patients require ventilators. Telemedical innovations and electronic intensive care

### Table 4. Incubation time for different coronaviruses including COVID-19

| Virus Name  | Incubation Period (Typical Cases) in Days |
|-------------|------------------------------------------|
| COVID-19    | 2-14                                     |
| SARS        | 2-7                                      |
| MERs        | 2-14                                     |
| Swine Flu   | 1-4                                      |
| Seasonal Flu| 1-4                                      |
unit (e-ICU) monitoring programs are ideal to fight Covid-19.[60] Epidemiologic investigations, risk assessment, surveillance, rapid diagnostic tests and vigilance (Fig. 9) are required by all countries to combat the potential outbreak.[61] In this pandemic, specific recommendations have been suggested for allocating medical resources such as maximize benefits, prioritize health workers, be responsive to evidence and recognize research participation.[62]

Conclusion

Both N and S proteins are the most abundant proteins in SARS-CoV-2 and can be potential targets of covid-19. Combined studies on antimalarial drugs, regular administration of BCG vaccine, and geographical variation in temperature can help researchers to find potential solutions to combat Covid-19. The Covid-19 pandemic caused worldwide shortage of hospital beds, ICU beds, and ventilators. More and more epidemiologic studies are needed to address risk factors for infection, severity of disease and the efficacy of infection-control measures. These types of studies should help us refine and focus our efforts to control and treat Covid-19. The SARS-CoV-2 has a large economic and social impact on the human population. Several aspects of the covid-19 outbreak are not yet fully understood, including transmission dynamics and the full spectrum of clinical illness. We need to save lives now while also improving the way we respond to outbreaks in general. Governments and industries will need to come to an agreement: during a pandemic, vaccines and antivirals can’t simply be sold to the highest bidder. Prevention is the ultimate solution for saving lives from such a pandemic.

Disclosures

Peer-review: Externally peer-reviewed.

Conflict of Interest: None declared.

Acknowledgement: We acknowledge Mr. Kaushal Singh Dhaked (Master of Fine Art) for designing figure of local transmission among the human population. We would like to thank Mr. Prem Pal Singh (PhD in Electronics at JNU, Jaipur), Mr. Chandra Pal Uickey and Ms. Pooja Dhaker for their support. We dedicate this review article to the health community for fighting against SARS-CoV-2.

References

1. Coronavirus Update (Live): 1,621,771 Cases and 97,185 Deaths from COVID-19 Virus Pandemic - Worldometer [Internet]. [cited 2020 Apr 9]. p. 1. Available from: www.worldometers.info/coronavirus/
2. Antonio GE, Wong KT, Hui DSC, Lee N, Yuen EHY, Wu A, et al. Imaging of severe acute respiratory syndrome in Hong Kong. Am J Roentgenol 2003;181:11–7. [CrossRef]
3. Lefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, Smith DB. Virus taxonomy: The database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res 2018;46(D1):D708–17. [CrossRef]
4. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. N Engl J Med 2020;382:1199–207. [CrossRef]
5. Munster VJ, Koopmans M, van Doremalen N, van Riel D, de Wit E. A novel coronavirus emerging in China - Key questions for impact assessment. N Engl J Med 2020;382:692–4. [CrossRef]
6. Patients L, Taylor D, Lindsay AC, Halcox JP. correspondence Niacin Compared with Ezetimibe. N Engl J Med 2020;0–3.
7. Nelson Lee, David Hui, Alan Wu, Paul Chan, Peter Cameron, et al. A Major Outbreak of Severe Acute Respiratory Syndrome in Hong Kong. N Engl J Med 2003;1986–94. [CrossRef]
8. Assiri A, McGeer A, Perl TM, Price CS, Al Rabeeah AA, et al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med 2013;369:407–16. [CrossRef]
9. Memish ZA, Zumla AI, Al-Hakeem RF, Al-Rabeeah AA, Stephens GM. Family cluster of middle east respiratory syndrome coronavirus infections. N Engl J Med 2013;368:2487–94. [CrossRef]
10. Azhar EI, El-Kafrawy SA, Farraj SA, Hassan AM, Al-Saeed MS, et al. Evidence for camel-to-human transmission of MERS coronavirus. N Engl J Med 2014;370:2499–505. [CrossRef]
11. Cui J, Li F, Shi ZL. Origin and evolution of pathogenic coronavi-ruses. Nat Rev Microbiol [Internet]. 2019;17:181–92. Available from: http://dx.doi.org/10.1038/s41579-018-0118-9 [CrossRef]
12. Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the COVID-19 Outbreak. Curr Biol [Internet]. 2020;1–6. Available from: https://doi.org/10.1016/j.cub.2020.03.022 [CrossRef]
13. Coronavirus [Internet]. [cited 2020 Apr 10]. p. 1. Available from: www.who.int/health-topics/coronavirus#tab=tab_3
14. Drosten C, Günther S, Preiser W, Van der Werf S, Brodt HR, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome infection. N Engl J Med 2003;348:1967–76. [CrossRef]
15. Gates B. New engla nd journal. 2020;1–3.
16. Duan H WS& YC. Coronavirus: limit short-term economic damage. Nature [Internet]. 2020;7796. Available from: https://www.nature.com/articles/d41586-020-00522-6 [CrossRef]
17. Gorbunova AE, Baker SC, Baric RS, de Groot RJ, Drosten C, et al. The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5(March). [CrossRef]
18. Ren L-L, Wang Y-M, Wu Z-Q, Xiang Z-C, Guo L, Xu T, et al. Identification of a novel coronavirus causing severe pneumonia in human. Chin Med J (Engl). 2020;1.
19. Lu R, Zhao X, Li J, Niu P, Yang B, et al. Genomic characteriza-tion and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet [Internet]. 2020;395:565–74. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30251-8 [CrossRef]
20. Perlman S. Another Decade, Another Coronavirus. N Engl J Med 2020;382:758–60. [CrossRef]
21. David M. Morens, M.D., Peter Daszak, Ph.D., and Jeffery K. Taubenberger, M.D. PD. Escaping Pandora's Box — Another Novel Coronavirus. N Engl J Med 2020;1–3.
22. Ranjit Sah AJR-M. Complete Genome Sequence of a 2019 Novel Coronavirus (SARS-CoV-2) Strain Isolated in Nepal. Am J Microbiol 2020;9:169–20. [CrossRef]
23. Zhu N, Zhang D, Wang et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. [CrossRef]
24. Wen F, Yu H, Guo J, Al E. Identification of the hyper-variable genomic hotspot for the novel coronavirus SARS-CoV-2. J Infect. 2020;27–9. [CrossRef]
25. Maier HJ, Bickerton E, Britton P. Coronaviruses: Methods and protocols. Coronaviruses Methods Protoc 2015;1–282.
26. Yin C. Genotyping coronavirus SARS-CoV-2: methods and implications. 2020;19:1–12. Available from: http://arxiv.org/abs/2003.10965
27. Walls AC, Park YJ, Al E. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell [Internet]. 2020;1–12. Available from: https://doi.org/10.1016/j.cell.2020.02.058
28. Bonavia A, Zelus BD, Wentworth DE, Talbot PJ, Holmes K V. Identification of a Receptor-Binding Domain of the Spike Glycoprotein of Human Coronavirus HCoV-229E. J Virol 2003;77:2530–8. [CrossRef]
29. Taguchi F, Kubo H, Suzuki H, Yamada YK. Localization of neutralizing epitopes and receptor-binding site in murine coronavirus spike protein. Adv Exp Med Biol 1995;380:359–65.
30. Zhou P, Yang X Lou, Wang XG. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Internet]. 2020;579(7798):270–3. Available from: http://dx.doi.org/10.1038/s41586-020-2012-7 [CrossRef]
31. Simmons G, Gosalia DN, Rennekamp AJ, Reeves. Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry. Proc Natl Acad Sci USA. 2005;102:11876–81. [CrossRef]
32. Kuhn JH, Li W, Choe H, Farzan M. Angiotensin-converting enzyme 2: A functional receptor for SARS coronavirus. Cell Mol Life Sci 2004;61:2738–43. [CrossRef]
33. Pragya D. Yadav, Varsha A. Potdar, Manohar Lal Choudhary, Dimpal A. Nyayaniat MA, Santosh M. Jadhav et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. INDIAN J MED RES 2020;21:1–9.
34. Holshue ML, DeBolt C, Lindquist S, Lofy KH. First case of 2019 novel coronavirus in the United States. N Engl J Med 2020;382:929–36. [CrossRef]
35. Pongpirul WA, Pongpirul K, Ratnarathon AC, Prasithsirikul W. Journey of a Thai Taxi driver and novel coronavirus. N Engl J Med 2020;382:1067–8. [CrossRef]
36. Ying-Chu Liu C-HL. A Locally Transmitted Case of SARS-CoV-2 Infection in Taiwan. N Engl J Med 2020;382:1068–70. [CrossRef]
37. Kumar D. Corona Virus: A Review of COVID-19. Eurasian J Med Oncol 2020;4:8–25. [CrossRef]
38. Rose C. Am I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out When a Doctor Comes Home. N Engl J Med 2020;1–3. [CrossRef]
39. Rosenbaum L. Facing Covid-19 in Italy — Ethics, Logistics, and Therapeutics on the Epidemic’s Front Line. N Engl J Med 2020;1–3. [CrossRef]
40. Sebastian H, Holger R, Annemarie B, Kortenbusch M, et al. Correspondence Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan , China. N Engl J Med [Internet]. 2020;1–3. Available from: https://www.nejm.org/doi/pdf/10.1056/NEJMc2001899?articleTools=true
41. Rothe C, Schunk M, Sothmann P, Bretzel G, Frosch G, Wallruch C, et al. Transmission of 2019-NCOV infection from an asymptomatic contact in Germany. N Engl J Med 2020;382:970–1.
42. Coronavirus Graphs: Worldwide Cases and Deaths - Worldometer [Internet]. 2020 [cited 2020 Apr 8]. p. 1. Available from: www.worldometers.info/coronavirus/worldwide-graphs/#countriess-cases
43. Jiaxin Zhou, Peng Wu. Correspondence Detection of Covid-19 in Children in Early January 2020 in Wuhan, China. N Engl J Med 2020;2019–21.
44. Molinaro GA, Lee P, Lee DA. c or r e sp ondence Rotavirus Vaccines. J Infect Dis 2006;1747–51.
45. Wiebe A, Longbottom J, Gleave K, Shearer FM, Sinka ME, Massey NC, et al. Geographical distributions of African malaria vector sibling species and evidence for insecticide resistance. Malar J 2017;16:1–10. [CrossRef]
46. RENKEN E. Map: How Many Cases Of Coronavirus Are There In Each U.S. State? : Shots - Health News : NPR. 2020 Apr 8;1. Available from: https://www.npr.org/sections/health-shots/2020/03/16/816707182/map-tracking-the-spread-of-the-coronavirus-in-the-u-s
47. Zwerling A, Behr MA, Verma A, Brewer TF, Menzies D, Pai M. Correspondence Are we Treating and Preventing Coronavirus Infection in Taiwan. N Engl J Med [Internet]. 2020;9:382. Available from: https://doi.org/10.1056/NEJMc2001899?articleTools=true
48. Rose C. Am I Part of the Cure or Am I Part of the Disease? Keeping Coronavirus Out When a Doctor Comes Home. N Engl J Med 2020;1–3. [CrossRef]
49. Desforges M, Le Coupanec A, Dubeau P, Bourgouin A, Lajoie L. The BCG world atlas: A database of global BCG vaccination policies and practices. PLoS Med 2011;8. [CrossRef]
50. Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe Acute Respiratory Syndrome Coronavirus Infection Causes Neuronal Death in the Absence of Encephalitis in Mice Transgenic for Human ACE2. J Virol 2008;82:7264–75. [CrossRef]
52. WHO | Novel Coronavirus [Internet]. 2020 [cited 2020 Apr 10]. Available from: www.who.int/csr/don/archive/disease/novel_coronavirus/en/

53. Drosten C, Meyer B, Müller MA, Corman VM, Al-Masri et al. Transmission of MERS-coronavirus in household contacts. N Engl J Med 2014;371:828–35. [CrossRef]

54. Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Heal [Internet]. 2020;2019–20. Available from: http://dx.doi.org/10.1016/S2214-109X(20)30114-5

55. Rothstein MA, Coughlin CN. Ensuring compliance with quarantine by undocumented immigrants and other vulnerable groups: Public health versus politics. Am J Public Health. 2019;109:1179–83. [CrossRef]

56. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G. A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;1–13.

57. The Times of India. Rajasthan doctors cure coronavirus patient with HIV drugs. 2020;1–21. Available from: https://timesofindia.indiatimes.com/city/jaipur/city-docs-cure-corona-patient-with-hiv-drugs/articleshow/74584859.cms

58. Seema M. T Cell Epitope-Based Vaccine Design for Pandemic Novel Coronavirus 2019-nCoV. Chemrxiv [Internet]. 2020; Available from: https://chemrxiv.org/articles/T_Cell_Epitope-Based_Vaccine_Design_for_Pandemic_Novel_Coronavirus_2019-nCoV/12029523

59. Robert D. Truog, Christine Mitchell, R.N., and George Q. Daley MD. The Toughest Triage — Allocating Ventilators in a Pandemic. N Engl J Med 2020;1–3.

60. Judd E. Hollander, M.D., and Brendan G. Carr MD. Perspective: Virtually Perfect? Telemedicine for Covid-19. 2020;1–3. Available from: NEJM.org [CrossRef]

61. Zaki AM, Van Boheemen S, Bestebroer TM, Osterhaus ADME, Fouchier RAM. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367:1814–20.

62. Emanuel EJ, Persad G, Upshur R, Thome B, Parker M et al. Fair Allocation of Scarce Medical Resources in the Time of Covid-19. N Engl J Med 2020;1–7. [CrossRef]